CTY — City Therapeutics, Inc.
CTY dilution and offerings
- Last offering: S-1MEF (Oct 2026)
- Float: 45.9M shares
$20.71-6.46%
Last close: · regular session
Last 11 sessions
Recent offering filing (S-1MEF, Oct 2026). Float: 45.9M shares. Latest SEC filing: SCHEDULE 13G on Oct 26, 2026. CTY closed at $20.71 (-6.46%) on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CTY in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Pharmaceutical Preparations
- Country: US
- Exchange: NASDAQ
- Website: https://www.citytx.com
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
Latest SEC filings for CTY
Latest CTY news
- RNAi drug developer City climbs after upsized IPO Read article
- RNAi drugmaker City prices upsized IPO at $18 per share Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.